Depotentiation in People With Focal Hand Dystonia

Sponsor
National Institute of Neurological Disorders and Stroke (NINDS) (NIH)
Overall Status
Terminated
CT.gov ID
NCT02106936
Collaborator
Prachaya Srivanitchapoom, MD (Other)
6
1
39.5
0.2

Study Details

Study Description

Brief Summary

Background:
  • Focal hand dystonia (FHD) causes muscles to contract, leading to abnormal movements or postures. Musicians, writers, and athletes often get it. Researchers want to study how patients with this condition learn, a process of the brain that depends on a property called plasticity.
Objective:
  • To study brain plasticity in people with FHD.
Eligibility:
  • Right-handed adults 18 years and older with FHD.

  • Healthy, right-handed adult volunteers.

Design:
  • Participants will be screened with medical history, physical exam, pregnancy test, and questionnaire about their right-handedness.

  • Participants will have 2 study visits on 2 different days.

  • Participants will sit in a chair and have up to 30 Transcranial Magnetic Stimulation (TMS) pulses on the left side of the head. A brief electrical current passes through a wire coil on the scalp. They will hear a click and may feel a pulling on the skin or muscle twitches. They may have to keep their eyes open and remain alert, tense certain muscles, or perform simple finger movements.

  • Forty more pulses, with 10 seconds between, will be given on the left side of the head. Some will be small, some big.

  • Researchers will measure muscle response through small electrodes taped to the right hand.

  • A cloth cap will be put on the participant s head. Researchers will write on tape on the cap.

  • Participants will have the r-PAS. An electrical stimulator will be placed on the nerve at the right wrist. Repeated magnetic pulses will be delivered in trains or short bursts together with electrical stimulation of nerve. Participants will receive up to 840 pulses.

  • Participants will be contacted after a few days for a follow-up check.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Objectives:
    Primary objectives:

    To explore the proper parameters creating a long-term depression (LTD)-like effect and depotentiation (DePo) by using rapid paired associative stimulation (rPAS) in focal hand dystonia (FHD) patients

    Sample Size and Population:

    We plan to recruit 28 healthy volunteers (HVs) and 28 FHD patients from the Movement Disorders and Botulinum Toxin (BoNT) clinics of HMCS.

    Design:

    Phase 1 deals with HVs while phase 2 deals with FHD patients. We will complete phase 1 before starting phase 2. Each phase is composed of 2 experiments. In phase 1, experiments 1 and 2 will create the LTD-like effect and DePo in HVs and in phase 2, experiments 3 and 4 will elicit the LTD-like effect and DePo in FHD patients. We will use regression analysis to show that the motor evoked potential (MEP) amplitude declines after eliciting the LTD-like effect and DePo.

    Outcome measurements:
    Primary outcome:

    Determining the parameters for creating the LTD-like effect and DePo in HVs and FHD using rPAS

    Secondary outcome:

    Measuring the percent change of the MEP amplitude after applying the proper stimulus parameters causing an LTD-like effect and DePo in both HVs and FHD.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    6 participants
    Observational Model:
    Other
    Time Perspective:
    Prospective
    Official Title:
    Depotentiation in Focal Hand Dystonia Patients
    Study Start Date :
    Mar 5, 2014
    Actual Primary Completion Date :
    Jun 20, 2017
    Actual Study Completion Date :
    Jun 20, 2017

    Outcome Measures

    Primary Outcome Measures

    1. Motor evoked potential amplitude [Immediate]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    • INCLUSION CRITERIA:

    • Must be 18 years or older

    • Must be right-handed

    • FHD includes only writer s cramp

    • Must be able to provide consent

    • No open scalp wounds or scalp infections.

    • Agrees to not drink caffeine or alcohol for 48 hours before study session.

    EXCLUSION CRITERIA:
    • Has used illegal drugs within the past 6 months based on history. The intent is to exclude those with drug use that may affect study results. Participants who appear to be intoxicated at the time of testing will be rescheduled.

    • Has more than 7 alcoholic drinks a week in the case of a woman and 14 alcoholic drinks a week in the case of a man.

    • Abnormal findings on neurologic exam (other than dystonia in patient group)

    • Has had a brain tumor, a stroke, head trauma, epilepsy or a history of seizures.

    • Has major depression or any major mental disorders (axis I disorders)

    • Has a neurologic disorder other than dystonia

    • Has had a head injury where there was a loss of consciousness for more than a few seconds.

    • Has metal in the body, such as a cardiac pacemaker, brain stimulator, shrapnel, surgical metal, clips in the brain, cochlear implants, or metal fragments in the eye,

    • Has known hearing loss.

    • Pregnancy and lactation

    • Taking any medication that acts as a central nervous system stimulant or that is known to lower seizure threshold, including, imipramine, amitriptyline, doxepine, nortriptyline, maprotiline, chlorpromazine, clozapine, foscarnet, ganciclovir, ritonavir, amphetamines, cocaine, (MDMA, ecstasy), phencyclidine (PCP, angel s dust), ketamine, gamma-hydroxybutyrate (GHB), alcohol, theophylline, mianserin, fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, reboxetine, venlafaxine, duloxetine, bupropion, mirtazapine, fluphenazine, pimozide, haloperidol, olanzapine, quetiapine, aripiprazole, ziprasidone, risperidone, chloroquine, mefloquine, imipenem, penicillin, ampicillin, cephalosporins, metronidazole, isoniazid, levofloxacin, cyclosporin, chlorambucil, vincristine, methotrexate, cytosine arabinoside, BCNU, lithium, anticholinergics, antihistamines, and sympathomimetics.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda Maryland United States 20892

    Sponsors and Collaborators

    • National Institute of Neurological Disorders and Stroke (NINDS)
    • Prachaya Srivanitchapoom, MD

    Investigators

    • Principal Investigator: Mark Hallett, M.D., National Institute of Neurological Disorders and Stroke (NINDS)

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    National Institute of Neurological Disorders and Stroke (NINDS)
    ClinicalTrials.gov Identifier:
    NCT02106936
    Other Study ID Numbers:
    • 140070
    • 14-N-0070
    First Posted:
    Apr 8, 2014
    Last Update Posted:
    Jul 2, 2017
    Last Verified:
    Jun 20, 2017
    Keywords provided by National Institute of Neurological Disorders and Stroke (NINDS)
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 2, 2017